View Cart

Certified Resume Writers | Professional Resume Writing Service ~ Starting at Only $99!

The sample below is for Chief Medical Officer Resume Sample. This resume was written by a ResumeMyCareer professional resume writer, and demonstrates how a resume for a Chief Medical Officer Resume Sample should properly be created. Our Certified Professional Resume Writers can assist you in creating a professional document for the job or industry of your choice. A professional resume writing service can significantly increase your changes of securing employment in a quick time manner.

Get Started Now!


Accomplished and dynamic professional eager to contribute management and operational expertise towards supporting the organization in driving business growth and increasing bottom-line profits as a key team member with extensive experience innovating vaccine delivery technologies, adjuvant and vaccine development. A highly dedicated individual and a proven leader with documented success in progressively dynamic and challenging positions, with working knowledge of the principles and techniques of effective supervision. Strategic thinker and results-oriented recognized ability to handle various organizational functions and lead productive teams in exceeding company goals. Excellent analytical skills with keen attention to detail, ability to analyze situations, and research information to develop sound and ethical business solution. A team player with effective interpersonal and communication skills, adept at building productive relationships and building rapport with a diverse set of individuals.

Core Competencies
Organizational Leadership • Operations Management • Time Management • Research & Analysis • Administrative Functions • Team Management • Client Relationship • Customer Service • Project Management • Product Development


• Excels in organizational planning. Delivers excellence in research and development, healthcare, administration and management.
• Able to work collaboratively with others, gather information, solicit feedback, and implement appropriate course of action to ensure best outcomes.
• Offers unparalleled integrity, initiative, resourcefulness, consistency, and diligence in achieving objectives and both short and long-term goals.
• Results-oriented, able to balance multiple responsibilities, consistently delivering results on time.
• Natural communicator with strong motivational skills and the ability to support operational goals and meet objectives.
• Adept at leading by example, marshaling resources and creating professional atmosphere to accomplish objectives.
• Exceptional ability to build and develop professional relationships.
• Proven ability to conduct medical research, devise and conduct experiments, process and analyze results and data.
• Proficient in developing original solutions to problems.
• Ability to collaborate with industry/academia to apply results of research and develop new techniques, products or practices.
• Successfully developed respiratory synctial virus, influenza, ETEC, anthrax, tetanus, malaria, HIV, H. pylori, TB, biodefense and cancer immunotherapy vaccines.


Novavax 2010 – 2012
Senior Vice President and Chief Medical Officer

Intercell 2008 – 2010
Chief Scientific Officer

Iomai Corporation, Gaithersburg MD 1998 – 2008
Senior Vice President & Scientific Director

Iomai Corporation, Washington DC 1997 – 1998
Founder/Scientific Director

Kaiser Permanente Group MD 1993 – 1996
Pediatrician, AHC

Walter Reed Army Medical Center, Washington DC 1993 – 1996
Attending Pediatrician/Pediatric Clinic

Walter Reed Army Institute of Research, Washington DC 1992 – 1997
Clinician-Research Scientist, Department of Membrane Biochemistry
Honorably Discharged, Lieutenant Colonel, US ARMY

34th General Hospital, Augsburg Germany 1990 – 1992
Staff Pediatrician
Madigan Army Medical Center, Tacoma WA 1989 – 1990
PL-3, Pediatrics

Miami Children’s Hospital, Miami FL 1987 – 1989
PL-1, PL-2

Alexander and Alexander, Riyadh, Saudi Arabia 1980 – 1983
Administrative Assistant

Mountlake Christian School, Seattle WA 1979 – 1980
Secondary School Instructor

Whitman College, Walla Walla WA 1977 – end-date
Intercollegiate Women’s Soccer Coach

California Sunshine, Anaheim CA 1977- end-date
Professional Soccer Player


BA Biology-Chemistry, 1972-1977
Whitman College, Walla Walla, WA

Diploma in Christian Studies, 1978-1991
Regent College, Vancouver, B.C., Canada

Doctor of Medicine, 1983-1987
Oral Roberts University School of Medicine, Tulsa, OK


Pediatrics Year 1, 2 Miami Children’s Hospital, Coral Gables, FL, 1987-1989
Pediatrics Year 3, Madigan Army Medical Center, Ft. Lewis, WA, 1989-1990
Diplomate of the American Board of Pediatricians (44530), 1990


Medical Research Fellowship, Walter Reed Army Institute of Research, Washington, DC, 1992-1993


1. Armstrong, R. B, Glenn, G. M, Laughlin, M. H. Disassociation between rat fiber activity and blood flow at the initiation of locomotory exercise. Clin. Physiol. 5(Suppl. 4):133, 1985.
2. Glenn, G.M., Laughlin, M.H., Armstrong, R.B. Muscle blood flow and fiber activity in partially curarized rats during exercise. J. Appl. Physiol. 63:1450-1456, 1987.
3. Glenn, G.M., Hayes, D.A., Armstrong, R.B. Verapamil-induced creatine kinase loss from rat slow and fast muscles. Res. Comm. Chem. Path. Pharmcol. 69:353-356, 1990.
4. Glenn, G.M., Krober, M. Group B streptococcal supraglottitis. Clin. Ped. 29:674-676, 1990.
5. Glenn, G.M., Vallier, G.T., Dorn, R., Kopp, J., Wood, B.P. Reflex sympathetic dystrophy. Am. J. Dis. Child 147(7):787-788, 1993.
6. Armstrong, R.B., Duan, C., Delp, M.R., Hayes, D.A., Glenn, G.M., Allen, G.D. Elevations in rat soleus muscle [Ca2+] with passive stretch. J. Appl. Physiol. 74(6):2990-2997, 1993.
7. Glenn, G.M., Krober, M., Kelley, P., McCarty, J., Weir, M.R. Pyridoxine as therapy in theophylline-induced seizures. Vet. Hum. Tox. 37:342-345, 1995.
8. Wang, R., Charoenvit, Y., Corradin, G., Porrozzi, R., Hunter, R.L., Glenn, G.M., Alving, C.R., Church, P., Hoffman, S.L. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 154:2784-2793, 1995.
9. Alving, C.R., Koulchin, V., Glenn, G.M., Rao, M.R. Liposomes as carriers of peptide antigens: Induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145:5-31, 1995.
10. Glenn, G.M., Rao, M.R., Richards, R.L., Matyas, G.M., Alving, C.R. Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. Immunol. Lett. 47:73-78, 1995.
11. Glenn, G.M. Salter-Harris fractures. In: Pearls and Pitfalls in Emergency Medicine, L.B. Stack, ed., Clinical Communications, Greenwich, CT, 1995.

12. Glenn, G.M., Alving, C.R. Macrophage activation by liposomes containing lipid A: Implications for vaccines. J. Liposome Res. 6:325-338, 1996.
13. Stoute, J.A., Ockenhouse, C.F., Sun, P.F., Lanar, D.E., Wellde, B.T., Hall, B.T., Kester, K., Magill, A., Krzych, U., Farley, L., Wirtz, R.A., Sadoff, J.C., Kaslow, D.C., Kumar, S., Church, L.W., Crutcher, J.M., Wizel, B., Hoffman, S., Lalvani, A., Hill, A.V., Tine, J.A., Guito, K.P., Glenn, G.M., Le, T.P., de Taisne, C., Anders, R., Ballou, W.R. A
preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336(2):86-91, 1997.
14. Le, T.P., Church, L.W.P., Corradin, G., Hunter, R.L., Charoenvit, Y., Wang, R., de la Vega, P., Sacci, J., Ballou, W.R., Kolodny, N., Kitov, S., Glenn, G.M., Richards, R. L., Alving, C.R., Hoffman, S.L. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine 16:305-312, 1998.
15. Richards, R.L., Rao, M., Wassef, N.M., Glenn, G. M., Rothwell, S. W., Alving, C.R. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun. 66:2859-6517, 1998.
16. Glenn, G.M., Rao, M., Matyas, G.R., Alving, C.R. Skin immunization made possible by cholera toxin. Nature 391(6670):851, 1998.
17. Glenn, G.M., Scharton-Kersten, T., Vassell, R.A., Mallet, C.P., Hale, T.L., Alving, C.R. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 61(7):3211-3214, 1998.
18. Glenn, G.M., Scharton-Kersten, T., Vassel, R., Alving, C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and Adjuvants. Infect. Immun. 67(3):1100-1106, 1999.
19. Scharton-Kersten, T., Glenn, G. M., Vassell, R., Yu, J., Walwender, D., Alving, Carl R. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine 17:S37-S43, 1999.
20. Glenn, G.M., Scharton-Kersten, T., Alving, C.R. Advances in vaccine delivery: transcutaneous immunization. Exp. Opin. Invest. Drugs 8(6):797-805, 1999.
21. Glenn, G. M., Taylor, D.N., Lang, D. Transcutaneous immunization: A new vaccine delivery strategy. In: The Jordan Report 2000: Accelerated Development of Vaccines, NIAID, U.S. Division of Microbiology and Infectious Diseases, Bethesda, MD, p. 91-93.
22. Glenn, G.M., Taylor, D.N., Li, X., Frankel, S., Montemarano, A., Alving, C.R. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat. Med. 6(12):1403-1406, 2000.
23. Glenn, G. M., Scharton-Kersten, T., Vassell, R. Transcutaneous immunization. In: Methods in Molecular Medicine, Vol. 42., D.T. O’Hagan, ed., Humana Press, Totowa, 1999, p. 315-326.
24. Hammond, S.A., Tsonis, C., Sellins, K., Rushlow, K., Scharton-Kersten, T., Colditz, I., Glenn, G.M. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv. Drug Deliv. Rev. 43(1):45-55, 2000.
25. Scharton-Kersten, T., Yu, J., Vassell, R., O’Hagan, D., Alving, C.R., Glenn, G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68(9):5306-5313, 2000.
26. Chen, D., Colditz, I.G., Glenn, G.M., Tsonis, C.G. Induction of systemic immune responses in sheep by topical application of cholera toxin to skin. Vet. Immunol. Immunopathol. 77:191-199, 2000.
27. Hammond, S.A., Walwender, D., Alving, C.R., Glenn, G.M. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19:2701-2707, 2001.
28. Glenn, G.M. Transcutaneous immunization. In: New Vaccine Technologies, R. Ellis, ed., Landes Bioscience &, Georgetown, TX, 2001.
29. Hammond, S.A., Guébre-Xabier, M., Yu, J., Glenn, G.M. Transcutaneous immunization: An emerging route of immunization and potent immunostimulation strategy. Crit. Rev. Ther. Drug Carrier Sys. 18(5):71-94, 2001.
30. Yu, J., Cassels, F., Scharton-Kersten, T., Hammond, S.A., Hartman, A., Angov, E., Corthesy, B., Alving, C., Glenn, G. Transcutaneous immunization using colonization factor and heat labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70(3):1056-1068, 2002.
31. Güereña-Burgueño, F., Hall, E.R., Taylor, D.N., Cassels, FJ., Scott, D.A., Wolf, M.K., Roberts Z.J., Nesterova, G.V., Alving, C.R., Glenn, G.M. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70(4):1874-1880, 2002.
32. Chen, D., Colditz, I.G., Glenn, G.M., Tsonis, C.G. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep. Vet. Immunol. Immunopathol. 86(3-4):177-182, 2002.
33. Glenn, G.M. Transcutaneous immunization. In: Vaccine Delivery Strategies, G. Dietrich, W. Goebel, eds., Horizon Scientific Press, Wymondham, UK, 2002, p. 53-81.
34. Glenn, G.M., Kenney, R.T. Transcutaneous immunization. In: New Generation Vaccines, 3rd Ed., M. Levine, ed., Marcel Dekker, Inc., New York, NY, 2003, in press.
35. Glenn, G.M., Kenney, R.T., Ellingsworth, L.R., Frech, S.A., Hammond, S.A., Zoeteweij, J.P. Transcutaneous immunization and Immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2(2):253-267, 2003.
36. Guebre-Xabier, M., Hammond, S.A., Epperson, D.E., Yu, J., Ellingsworth, L., Glenn, G.M. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of dendritic cells. J. Virol. 77(9):5218-5225, 2003.
37. Glenn, G.M., Kenney, R.T., Hammond, S.A., Ellingsworth, L.R. Transcutaneous immunization and Immunostimulant strategies. In: Immunology & Allergy Clinics of North America: Vaccines in the 21st Century, S.E. Barth, ed., W. B. Saunders Co., Philadelphia, PA, in press.
38. Matyas, G.R., Friedlander, A.M., Glenn, G.M., Little, S., Yu, J., Alving, C.R. A needle-free skin patchvaccination method for anthrax. Infect. Immun., submitted.
39. Induction of protective immunity against lethal anthrax challenge with a patch.Kenney RT, Yu J, Guebre-Xabier M, Frech SA, Lambert A, Heller BA, Ellingsworth LR, Eyles JE, Williamson ED, Glenn GM. J Infect Dis. 2004 Aug 15;190(4):774-82.
40. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch.Frech SA, Kenney RT, Spyr CA, Lazar H, Viret JF, Herzog C, Glück R, Glenn GM.Vaccine. 2005 Jan 4;23(7):946-50.
41. Transcutaneous immunization and immunostimulant strategies. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Immunol Allergy Clin North Am. 2003 Nov;23(4):787-813. Review.
42. Needle-free skin patch vaccination method for anthrax. Matyas GR, Friedlander AM, Glenn GM, Little S, Yu J, Alving CR. Infect Immun. 2004 Feb;72(2):1181-3.

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.
Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA.
J Clin Invest. 2004 Apr;113(7):998-1007.

Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice.
Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM.
J Virol. 2004 Jul;78(14):7610-8.

GM1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvant.
Zoeteweij JP, Epperson DE, Porter JD, Zhang CX, Frolova OY, Constantinides AP, Fuhrmann SR, El-Amine M, Tian JH, Ellingsworth LR, Glenn GM.
J Immunol. 2006 Jul 15;177(2):1197-207.

Mass vaccination: solutions in the skin.
Glenn GM, Kenney RT.
Curr Top Microbiol Immunol. 2006;304:247-68. Review.

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.
Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA.
Infect Immun. 2007 May;75(5):2163-70.

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC):
protective efficacy in a double-blind, placebo-controlled challenge study.
McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM.
Vaccine. 2007 May 4;25(18):3684-91.

Adjuvants: progress, regress and pandemic preparedness.
Glenn GM, O’Hagan DT.
Expert Rev Vaccines. 2007 Oct;6(5):651-2.

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch.
Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC, Yu J.
Expert Rev Vaccines. 2007 Oct;6(5):809-19. Review.

Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization.
Mkrtichyan M, Ghochikyan A, Movsesyan N, Karapetyan A, Begoyan G, Yu J, Glenn GM, Ross TM, Agadjanyan MG,
Cribbs DH.
DNA Cell Biol. 2008 Jan;27(1):19-24.

Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga
Toxin subunit B.
Zhu C, Yu J, Yang Z, Davis K, Rios H, Wang B, Glenn G, Boedeker EC.
Clin Vaccine Immunol. 2008 Feb;15(2):359-66. Epub 2007 Nov 14.

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch.
Frolov VG, Seid RC Jr, Odutayo O, Al-Khalili M, Yu J, Frolova OY, Vu H, Butler BA, Look JL, Ellingsworth LR, Glenn GM.
Influenza Other Respi Viruses. 2008 Mar;2(2):53-60.

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.
Frerichs DM, Ellingsworth LR, Frech SA, Flyer DC, Villar CP, Yu J, Glenn GM.
Vaccine. 2008 May 23;26(22):2782-7. Epub 2008 Mar 28.

Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase II,
randomised, double-blind, placebo-controlled field trial.
Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez
Sandoval FG, Meléndez-Romero JH, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN,
Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM.
Lancet. 2008 Jun 14;371(9629):2019-25.

Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines.
Glenn GM, Francis DH, Danielsen EM.
Infect Immun. 2009 Dec;77(12):5206-15. Epub 2009 Sep 8. Review.

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a
heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.
Vaccine. 2009 Dec 30;27 Suppl 6:G60-6.

The ‘perfect’ adjuvant, a stronger voice.
Glenn GM.
Expert Rev Vaccines. 2011 Apr;10(4):399-400.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP,
Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.
Vaccine. 2011 Oct 13;29(44):7826-34. Epub 2011 Aug 2.

H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric
Form of Influenza Virus Hemagglutinin in Humans.
Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn
G, Golding H.
J Virol. 2011 Nov;85(21):10945-54. Epub 2011 Aug 24.


1. Rao, M.R., Glenn, G.M., Gross, M., Alving, C.R. Induction of T cell responses to liposomal encapsulated malaria antigens. 9th International Congress of Immunology, 1995.
2. Glenn, G.M., Richards, R.L., McGill, A., Alving, C.R. IgG1 subclass antibodies correlate with protection in liposomal malaria vaccine challenge trial. Abstract accepted for presentation at 3rd Annual IBC Vaccine Conference, February, 1996.

3. Glenn, G.M. IBC’s Novel Enabling Technologies for Vaccine Development, London, 1999.
4. Scharton-Kersten, T.M., Yu, J., Vassell, R., Alving, C.R., Glenn, G.M. Topical application of antigen to the skin surface rapidly induces antigen specific CD4+ T cell responses. CDC/NFID 2nd Annual Conference on Vaccine Research, Bethesda, MD, 1999.
5. Glenn, G.M. Transcutaneous immunization. IBC’s 4th International Symposium on Veterinary Vaccines, Buena Vista, FL, 1999.
6. Glenn, G.M. Transcutaneous immunization. Centers for Disease Control, 33rd National Immunization Conference, Dallas, TX, 1999.
7. Glenn, G. M. Transcutaneous immunization: Potent and practical access to the immune system via the skin. First Global Conference on Vaccines & Immunisation Into the Next Millenium, Manchester, England, 1999.
8. Glenn, G.M. Transcutaneous immunization. World Health Organization’s 12th Meeting of the Steering Committee on New Vaccination Approaches, Geneva, Switzerland, 1999.
9. Glenn, G.M., Taylor, D.N., Scharton-Kersten, T., Vassell, R., Alving, C.R. Transcutaneous immunization of humans using heat-labile enterotoxin of Escherichia coli. 35th Joint Conference of the U.S.-Japan Cholera and Other Bacterial Enteric Infections Joint Panel, Baltimore, MD, 1999.
10. Glenn, G.M. Transcutaneous immunization with cholera toxoid adjuvant. Sixth United Kingdon-Ireland Controlled Release Society Symposium on Novel Vaccine Formulations and Delivery Sytems, Dublin, Ireland, 2000.
11. Glenn, G.M. Transcutaneous immunization: An emerging route of immunization. Bio 2000 International Biotechnology Meeting & Exhibition, Boston, MA, 2000.
12. Glenn, G.M. Mucosal responses to skin immunization. Sixth National Symposium: Basic Aspects of Vaccines, Bethesda, MD, 2000.
13. Glenn, G.M. Transcutaneous immunization: Procedure exploiting the immunobiology of the skin. Millennium Second World Congress on Vaccines and Immunization, Liege, Belgium, 2000.
14. Glenn, G.M. Transcutaneous immunization. GAVI/WHO Workshop on New Technologies, Bethesda, MD, 2001.
15. Glenn, G.M. Transcutaneous immunization. 18th Annual International Pharmaceutical and Chemical Technology Forum, Reston, VA, 2001.
16. Glenn, G.M. Transcutaneous immunization: An emerging route of immunization and potent immunostimulation strategy. BIO 2001, San Diego, CA, 2001.
17. Glenn, G.M. Transcutaneous immunization. Controlled Release Society’s 28th International Symposium, San Diego, CA, 2001.
18. Glenn, G.M. Transcutaneous immunization: Targeting Langerhans cells with adjuvants. British Pharmacological Society Summer Meeting, University College Dublin, Ireland, 2001.
19. Glenn, G.M. Transcutaneous immunization: Using adjuvants on the skin to induce systemic immune responses. Gordon Research Conference on Barrier Function of Mammalian Skin, Roger Williams University, Bristol, RI, 2001.
20. Glenn, G.M. Transcutaneous immunization. Vaccines for Enteric Diseases, Tampere, Finland, 2001.
21. Glenn, G.M. Needle-free immunization using a patch: What happens when Langerhans cells are put to work. World Vaccine Congress, Lyon, France, 2001.
22. Glenn, G.M. Transcutaneous immunization: An emerging route of immunization and potent strategy for immunostimulation. Vaccines of the Future: From Rational Design to Clinical Development, Institut Pasteur Euroconferences, Paris, France, 2001.
23. Glenn, G.M. Transcutaneous immunization. Berna Biotech R&D Day, Berne, Switzerland, 2002.
24. Glenn, G.M. Transcutaneous immunization for bio-terror vaccines. BIO Defense & Homeland Security Procurement Conference, Arlington, VA, 2002.
25. Glenn, G.M. Transcutaneous immunization: Putting Langerhans cells to work. Phacilitate Vaccine Forum, Paris, France, 2002.
26. Glenn, G.M. Transcutaneous immunization. WHO/GAVI Global Vaccine Research Forum, Geneva, Switzerland, 2002.
27. Glenn, G.M. Transcutaneous immunization. Pharmacy and Pharmaceutical Sciences World Congress, Nice, France, 2002.
28. Glenn, G.M. Transcutaneous immunization: Moving a new innovation toward a product. World Vaccine Congress, Lyon, France, 2002.
29. Glenn, G.M. Transcutaneous immunization. WHO Steering Committee on New Vaccine Delivery Systems, Geneva, Switzerland, 2002.
30. Glenn, G.M. Transcutaneous immunization and immunostimulant patches. World Vaccine Congress, Montreal, Quebec, Canada, 2003.
31. Glenn, G.M. Transcutaneous immunization and Immunostimulant strategies: Capitalizing on the immunocompetence of the skin. The Future of Vaccines-Cancer Meets Infectious Diseases, Vienna, Austria, 2003.


Vaccine Delivery Systems
Enteric Diseases


Principal Investigator/Senior Contributor on the following grants:

DHHS BARDA Contract, 2006, 15,000,000
PI-Transcutaneous Immunization for Tetanus Booster, 1998, NIAID Phase 1 SBIR, $100,000
PI-Transcutaneous Immunization for DNA, 1998, NIAID Phase 1 SBIR, $100,000
HIV RAD: Structural approaches to vaccine development, 2001, NIH, $340,000
PI-Transcutaneous Immunization for Tetanus Booster, 2002, NIAID Phase 2 SBIR, $851,767
Development of Broad Platform Immunostimulatory Cancer Vaccine, 2002, NIST, $3,467,618
Skin Immunization with SIV and HIV Antigen, 2002, NIAID SBIR, $399,790
Transcutaneous Immunization for Tetanus Booster, 2003, NIAID Phase 2 SBIR, $811,042


U.S. Patent 5,910,306, “Transdermal Delivery System for Antigen,” June 8, 1999
WO99/43350, “Use of Penetration Enhancers and Barrier Disruption Agents,” August 25, 1999
U.S. Patent 5,980,898, “Adjuvant for Transcutaneous Immunization,” November 9, 1999
Brazilian Patent PI9712952-6, “Adjuvant for Transcutaneous Immunization,” December 7, 1999
WO00/61184, “Dry Formulation for Transcutaneous Immunization,” October 10, 2000
Canadian Patent 2,272,417, “Adjuvant for Transcutaneous Immunization,” January 19, 2000
New Zealand Patent 335749, “Adjuvant for Transcutaneous Immunization,” January 26, 2001
Australian Patent 744537, “Adjuvant for Transcutaneous Immunization,” June 13, 2002
WO02/74325, “Patch for Transcutaneous Immunization,” September 19, 2002


Meritorious Service Medal
Army Achievement Medal

Order From Us Securely at